DNER and hematologic disorder: However, some BET inhibitors as single-agent therapies have shown mixed outcomes in clinical trials for distinct cancer settings, despite their excellent results in preclinical models.488 For example, several phases 1 and 2 clinical trials investigating the therapeutic effect of birabresib on solid or hematological malignancies were terminated prematurely because of limited efficacy (NCT02698176, NCT02698189, NCT02698176, NCT02296476).